

Rohit Mehra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5724684/publications.pdf>

Version: 2024-02-01

172
papers

21,076
citations

31976

53
h-index

9861

141
g-index

173
all docs

173
docs citations

173
times ranked

21198
citing authors

#	ARTICLE	IF	CITATIONS
1	Precursors of urinary bladder cancer: molecular alterations and biomarkers. <i>Human Pathology</i> , 2023, 133, 5-21.	2.0	2
2	Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 4.e1-4.e7.	1.6	2
3	Molecular assessment of testicular adult granulosa cell tumor demonstrates significant differences when compared to ovarian counterparts. <i>Modern Pathology</i> , 2022, 35, 697-704.	5.5	9
4	Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature. <i>European Urology Oncology</i> , 2022, 5, 92-99.	5.4	5
5	Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates. <i>Asian Journal of Urology</i> , 2022, 9, 1-11.	1.2	11
6	TERT Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract. <i>European Urology Open Science</i> , 2022, 35, 74-78.	0.4	4
7	Renal cell carcinoma associated with tuberous sclerosis complex (TSC)/mammalian target of rapamycin (MTOR) genetic alterations. <i>Modern Pathology</i> , 2022, 35, 296-297.	5.5	13
8	Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. <i>Nature</i> , 2022, 601, 434-439.	27.8	110
9	Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. <i>Urology</i> , 2022, 167, 171-178.	1.0	4
10	Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. <i>BMC Cancer</i> , 2022, 22, 494.	2.6	8
11	Pathogenic ATM and BAP1 germline mutations in a case of early-onset, familial sarcomatoid renal cancer.. <i>Cold Spring Harbor Molecular Case Studies</i> , 2022, 8, .	1.0	2
12	De novo neuroendocrine features in prostate cancer. <i>Human Pathology</i> , 2022, 127, 112-122.	2.0	7
13	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	2.5	143
14	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 295.e1-295.e8.	1.6	6
15	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	1.9	93
16	Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 136-144.	1.6	52
17	In Vivo Evaluation of a Novel Pigtail Suture Stent. <i>Urology</i> , 2021, 148, 83-87.	1.0	10
18	Targeting transcriptional regulation of SARS-CoV-2 entry factors <i>ACE2</i> and <i>TMPRSS2</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	142

#	ARTICLE	IF	CITATIONS
19	A novel ATXN1-DUX4 fusion expands the spectrum of "CIC-rearranged sarcoma"™ of the CNS to include non-CIC alterations. <i>Acta Neuropathologica</i> , 2021, 141, 619-622.	7.7	16
20	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	5.5	118
21	De novo neuroendocrine transdifferentiation in primary prostate cancer—a phenotype associated with advanced clinico-pathologic features and aggressive outcome. <i>Medical Oncology</i> , 2021, 38, 26.	2.5	18
22	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	10.7	79
23	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	5.5	138
24	TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 1596-1607.	5.5	17
25	Immunohistochemical expression of PAX8 , PAX2 , and cytokeratin in melanomas. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 1246-1251.	1.3	6
26	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	136
27	Characterization of SARS-CoV-2 and host entry factors distribution in a COVID-19 autopsy series. <i>Communications Medicine</i> , 2021, 1, .	4.2	16
28	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. <i>Journal of Clinical Pathology</i> , 2021, 74, 291-299.	2.0	14
29	Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 450-462.	3.7	7
30	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	5.9	16
31	Notch3 promotes prostate cancer-induced bone lesion development via MMP-3. <i>Oncogene</i> , 2020, 39, 204-218.	5.9	29
32	PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates. <i>Modern Pathology</i> , 2020, 33, 1165-1171.	5.5	18
33	TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. <i>Pathology Research and Practice</i> , 2020, 216, 152663.	2.3	1
34	Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier. <i>Prostate</i> , 2020, 80, 146-152.	2.3	21
35	Should all prostate needle biopsy Gleason score 4+4=8 prostate cancers be high risk? Implications for shared decision-making and patient counselling. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 78.e1-78.e6.	1.6	6
36	Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literature. <i>Histopathology</i> , 2020, 76, 875-887.	2.9	7

#	ARTICLE	IF	CITATIONS
37	Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice. <i>Urology</i> , 2020, 145, 204-210.	1.0	3
38	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	3.0	2
39	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	7.1	49
40	Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 657-660.	1.9	10
41	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3024-3031.	1.6	26
42	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 735.	7.1	58
43	Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: observations from the Michigan Legacy Tissue Program. <i>Medical Oncology</i> , 2020, 37, 16.	2.5	13
44	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	3.9	17
45	Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. <i>European Urology</i> , 2020, 78, 63-74.	1.9	57
46	Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma. <i>Nature Communications</i> , 2020, 11, 1778.	12.8	50
47	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 332-339.e2.	1.9	5
48	Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study. <i>JCO Precision Oncology</i> , 2020, 4, 1386-1392.	3.0	4
49	Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. <i>Medical Oncology</i> , 2019, 36, 74.	2.5	15
50	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.	7.0	17
51	A Family With a Carotid Body Paraganglioma and Thyroid Neoplasias With a New SDHAF2 Germline Variant. <i>Journal of the Endocrine Society</i> , 2019, 3, 2151-2157.	0.2	6
52	Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile. <i>Diagnostic Pathology</i> , 2019, 14, 113.	2.0	8
53	Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019, 5, 975.	7.1	288
54	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 778-789.	0.8	247

#	ARTICLE	IF	CITATIONS
55	TFEB Expression Profiling in Renal Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1445-1461.	3.7	38
56	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6721-6730.	7.0	74
57	Contemporary Renal Tumor Categorization With Biomarker and Translational Updates: A Practical Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 1477-1491.	2.5	9
58	The utility of upper urinary tract urine cytology before and after application of the Paris system. <i>Diagnostic Cytopathology</i> , 2019, 47, 421-427.	1.0	19
59	Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile. <i>Modern Pathology</i> , 2019, 32, 701-709.	5.5	29
60	Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. <i>Human Pathology</i> , 2019, 86, 76-84.	2.0	16
61	Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements—a clinicopathologic and genomic sequencing-based discussion. <i>Medical Oncology</i> , 2019, 36, 27.	2.5	8
62	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. <i>Journal of Urology</i> , 2019, 201, 284-291.	0.4	18
63	Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. <i>Urology</i> , 2018, 117, 95-100.	1.0	26
64	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. <i>Medical Oncology</i> , 2018, 35, 21.	2.5	3
65	Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. <i>European Urology</i> , 2018, 74, 413-419.	1.9	29
66	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 279-292.	3.7	101
67	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , 2018, 188, 1478-1485.	3.8	119
68	Erectile function after stereotactic body radiotherapy for localized prostate cancer. <i>BJU International</i> , 2018, 121, 61-68.	2.5	24
69	The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. <i>Human Pathology</i> , 2018, 71, 47-54.	2.0	39
70	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. <i>Molecular Cancer Research</i> , 2018, 16, 1125-1137.	3.4	51
71	Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. <i>Modern Pathology</i> , 2018, 31, 179-197.	5.5	73
72	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018, 74, 107-114.	1.9	54

#	ARTICLE	IF	CITATIONS
73	A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. <i>European Urology</i> , 2018, 73, 763-769.	1.9	63
74	Comparative study of <i>TERT</i> promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma. <i>Histopathology</i> , 2018, 72, 354-356.	2.9	14
75	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1571-1584.	3.7	34
76	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-590.	1.6	162
77	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018, 36, 991-999.	1.6	169
78	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.	5.4	6
79	Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. <i>Medical Oncology</i> , 2018, 35, 152.	2.5	13
80	Glandular Tumors of the Urachus and Urinary Bladder: A Practical Overview of a Broad Differential Diagnosis. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1164-1176.	2.5	9
81	Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1202-1215.	2.5	39
82	Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples. <i>Cancer Cytopathology</i> , 2018, 126, 992-1002.	2.4	9
83	An Insight into the "Dark Matter" of Kidney Cancer. <i>European Urology</i> , 2018, 74, 764-766.	1.9	1
84	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. <i>Nature Genetics</i> , 2018, 50, 814-824.	21.4	196
85	Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 483-486.	1.9	86
86	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. <i>European Urology</i> , 2018, 74, 741-753.	1.9	54
87	Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. <i>European Urology</i> , 2018, 74, 529-531.	1.9	17
88	Acquired Cystic Disease-associated Renal Cell Carcinoma (ACD-RCC). <i>American Journal of Surgical Pathology</i> , 2018, 42, 1156-1165.	3.7	42
89	Challenges in Pathologic Staging of Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1253-1261.	3.7	22
90	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2017, 3, 502-509.	3.1	25

#	ARTICLE	IF	CITATIONS
91	Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. International Journal of Radiation Oncology Biology Physics, 2017, 98, 726-732.	0.8	11
92	Anatomical patterns of recurrence following biochemical relapse after postâ€prostatectomy salvage radiation therapy: a multiâ€institutional study. BJU International, 2017, 120, 351-357.	2.5	10
93	A distinctive, lowâ€grade oncocytic fumarate hydrataseâ€deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenaseâ€deficient renal cell carcinoma. Histopathology, 2017, 71, 42-52.	2.9	79
94	Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes. American Journal of Surgical Pathology, 2017, 41, 801-809.	3.7	33
95	Nephrogenic adenoma does not express <sc>Nkx</sc>3.1. Histopathology, 2017, 71, 669-671.	2.9	9
96	Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. Current Urology Reports, 2017, 18, 55.	2.2	15
97	Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA <i>In Situ</i> Hybridization Assay. Clinical Cancer Research, 2017, 23, 5622-5630.	7.0	31
98	Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma. Human Pathology, 2017, 67, 134-145.	2.0	38
99	Rare Presentation of Metastatic Cystic Trophoblastic Tumor in aâ€Patient Without Prior Chemotherapy. Urology Case Reports, 2017, 13, 154-157.	0.3	4
100	Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. Cell, 2017, 171, 1559-1572.e20.	28.9	200
101	Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. Immunotherapy, 2017, 9, 695-699.	2.0	0
102	Robotic-assisted Thoracoscopic Transdiaphragmatic Adrenalectomy (RATTA) for Metastatic Renal Cell Carcinoma. Urology, 2017, 105, 9-12.	1.0	1
103	Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. Journal of Urology, 2017, 197, 662-668.	0.4	76
104	Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers to reveal discordant genomic and transcriptomic events and unique therapeutic opportunities.. Journal of Clinical Oncology, 2017, 35, 296-296.	1.6	2
105	Involvement of p38-Î²/TrCP-Tristetraprolin-TNFÎ± axis in radiation pneumonitis. Oncotarget, 2017, 8, 47767-47779.	1.8	9
106	Independent surgical validation of the new prostate cancer gradeâ€grouping system. BJU International, 2016, 118, 763-769.	2.5	48
107	Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics. Prostate, 2016, 76, 845-853.	2.3	9
108	Comprehensive Immunophenotypic Characterization of Adult and Fetal Testes, the Excretory Duct System, and Testicular and Epididymal Appendages. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, e50-e68.	1.2	20

#	ARTICLE	IF	CITATIONS
109	Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. <i>Neoplasia</i> , 2016, 18, 489-499.	5.3	55
110	Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 415.e1-415.e6.	1.6	18
111	Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome. <i>American Journal of Surgical Pathology</i> , 2016, 40, 865-875.	3.7	182
112	Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. <i>Cancer Discovery</i> , 2016, 6, 1258-1266.	9.4	66
113	Prostatic Adenocarcinoma With Hormone Exposure Related Changes in a Patient With Hepatic Cirrhosis – Value of Autopsy in a Case Report. <i>Urology Case Reports</i> , 2016, 9, 37-40.	0.3	0
114	Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1026-1037.	2.5	53
115	Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1457-1472.	3.7	112
116	Renal Cell Carcinoma Occurring in Patients With Prior Neuroblastoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 989-997.	3.7	31
117	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358.	21.4	143
118	Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis. <i>Cancer Research</i> , 2016, 76, 1391-1402.	0.9	62
119	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. <i>Journal of Urology</i> , 2016, 196, 405-411.	0.4	89
120	Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. <i>European Urology Focus</i> , 2016, 1, 265-268.	3.1	45
121	Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. <i>European Urology</i> , 2016, 70, 549-552.	1.9	121
122	Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. <i>Modern Pathology</i> , 2016, 29, 157-165.	5.5	31
123	MP1-14 DEFINING ADVERSE PATHOLOGY FOR LOWER RISK MEN UNDERGOING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2015, 193, .	0.4	1
124	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	28.9	2,660
125	Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. <i>Cancer Research</i> , 2015, 75, 5219-5227.	0.9	94
126	Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 297-311.	2.8	43

#	ARTICLE	IF	CITATIONS
127	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. <i>Asian Journal of Urology</i> , 2015, 2, 53-58.	1.2	12
128	Molecular and Immunohistochemical Characterization Reveals Novel BRAF Mutations in Metanephric Adenoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 549-557.	3.7	43
129	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 5619-5629.	7.0	56
130	The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. <i>Genome Research</i> , 2015, 25, 1372-1381.	5.5	139
131	Metastases to the kidney: a clinicopathological study of 43 cases with an emphasis on deceptive features. <i>Histopathology</i> , 2015, 66, 587-597.	2.9	32
132	Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia. <i>Urology Case Reports</i> , 2015, 3, 98-100.	0.3	2
133	Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. <i>Medical Oncology</i> , 2015, 32, 249.	2.5	10
134	MiT Family Translocation-Associated Renal Cell Carcinoma: A Contemporary Update With Emphasis on Morphologic, Immunophenotypic, and Molecular Mimics. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1224-1233.	2.5	55
135	The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. <i>Cancer Research</i> , 2015, 75, 3720-3727.	0.9	276
136	Emerging Entities in Renal Neoplasia. <i>Surgical Pathology Clinics</i> , 2015, 8, 623-656.	1.7	21
137	Investigating the long noncoding RNA SchLAP1 as a prognostic tissue and urine biomarker in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7-7.	1.6	1
138	Prognostic significance of perineural invasion in localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 30-30.	1.6	0
139	Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy (NAC) in urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 313-313.	1.6	2
140	A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SchLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer. <i>Neoplasia</i> , 2014, 16, 1121-1127.	5.3	81
141	Frequent discordance between <i>ERG</i> gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. <i>Prostate</i> , 2014, 74, 1199-1208.	2.3	33
142	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SchLAP1. <i>Lancet Oncology</i> , The, 2014, 15, 1469-1480.	10.7	226
143	Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63, Tj ETQq1 1, 0.784314 rgBT /Cv	3.7	31
144	Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC). <i>American Journal of Surgical Pathology</i> , 2014, 38, 567-577.	3.7	48

#	ARTICLE	IF	CITATIONS
145	Tuberous Sclerosis-associated Renal Cell Carcinoma. American Journal of Surgical Pathology, 2014, 38, 1457-1467.	3.7	211
146	Current and Proposed Molecular Diagnostics in a Genitourinary Service Line Laboratory at a Tertiary Clinical Institution. Cancer Journal (Sudbury, Mass), 2014, 20, 29-42.	2.0	16
147	Primary Urethral Clear-Cell Adenocarcinoma. American Journal of Pathology, 2014, 184, 584-591.	3.8	46
148	Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. Human Pathology, 2014, 45, 1139-1146.	2.0	25
149	HRAS mutations are frequent in inverted urothelial neoplasms. Human Pathology, 2014, 45, 1957-1965.	2.0	39
150	Understanding the Relationship Between Tumor Size, Gland Size, and Disease Aggressiveness in Men With Prostate Cancer. Urology, 2014, 84, 373-379.	1.0	14
151	Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function. Blood, 2014, 124, 142-150.	1.4	52
152	Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. Translational Oncology, 2013, 6, 405-412.	3.7	13
153	Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer, 2013, 119, 3287-3294.	4.1	51
154	The mutational landscape of lethal castration-resistant prostate cancer. Nature, 2012, 487, 239-243.	27.8	2,128
155	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. Cancer Cell, 2011, 19, 664-678.	16.8	397
156	Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 3924-3932.	7.0	69
157	Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer. Neoplasia, 2010, 12, 590-IN21.	5.3	305
158	Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Modern Pathology, 2009, 22, 1083-1093.	5.5	209
159	Tomlins et al. reply. Nature, 2009, 457, E2-E3.	27.8	6
160	Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. Neoplasia, 2008, 10, 177-IN9.	5.3	608
161	Characterization of <i>TMPRSS2</i> -ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer. Cancer Research, 2008, 68, 3584-3590.	0.9	249
162	Characterization of <i>TMPRSS2:ETV5</i> and <i>SLC45A3:ETV5</i> Gene Fusions in Prostate Cancer. Cancer Research, 2008, 68, 73-80.	0.9	244

#	ARTICLE	IF	CITATIONS
163	Heterogeneity of <i>TPMRSS2</i> Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular Evidence for an Independent Group of Diseases. <i>Cancer Research</i> , 2007, 67, 7991-7995.	0.9	197
164	Comprehensive assessment of <i>TPMRSS2</i> and ETS family gene aberrations in clinically localized prostate cancer. <i>Modern Pathology</i> , 2007, 20, 538-544.	5.5	281
165	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. <i>Nature</i> , 2007, 448, 595-599.	27.8	743
166	<i>TPMRSS2:ETV4</i> Gene Fusions Define a Third Molecular Subtype of Prostate Cancer. <i>Cancer Research</i> , 2006, 66, 3396-3400.	0.9	432
167	Recurrent Fusion of <i>TPMRSS2</i> and ETS Transcription Factor Genes in Prostate Cancer. <i>Science</i> , 2005, 310, 644-648.	12.6	3,541
168	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. <i>Cancer Cell</i> , 2005, 8, 393-406.	16.8	731
169	Identification of <i>GATA3</i> as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis. <i>Cancer Research</i> , 2005, 65, 11259-11264.	0.9	272
170	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. <i>Cancer Research</i> , 2004, 64, 9209-9216.	0.9	816
171	The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. <i>Oncotarget</i> , 0, 7, 41217-41232.	1.8	57
172	Clinicopathologic Spectrum of Secondary Solid Tumors of the Prostate of Nonurothelial Origin. <i>American Journal of Surgical Pathology</i> , 0, Publish Ahead of Print, .	3.7	0